Document Detail

Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial.
MedLine Citation:
PMID:  18272089     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Some physicians prescribe corticosteroids as adjunctive therapy for patients with migraine headaches to decrease the rate of rebound headache. The efficacy of this practice has not been tested. Our objective is to determine the efficacy of single-dose dexamethasone as adjunctive therapy for emergency medicine patients with migraine headache in preventing headache recurrence at 3 and 30 days posttreatment. METHODS: From November 2004 to November 2005, we conducted a multicenter, double-blinded, placebo-controlled randomized clinical trial of adult patients who met the International Headache Society definition of migraine headache. After informed consent, patients were randomly assigned to one of two groups: receiving either placebo or 24 mg dexamethasone intravenously. To ensure generalizability, all other aspects of patient care were left to the discretion of the emergency physician. Clinical and demographic information was obtained; and patients were subsequently contacted at both 3 and 30 days to determine headache recurrence, current functional disability, and need for return to the ED. Our primary outcome measures were the recurrence of migraine headache at 3 and 30 days. We used Fisher exact to test for statistical significance. RESULTS: A total of 115 patients were enrolled, with 16 patients lost to follow-up at 3 days and 3 additional patients lost at 30 days. Baseline characteristics as well as adverse event profiles were equivalent in both study groups. At 3-day follow-up, 45% (95% confidence interval [CI] 31%-60%) of the placebo group had recurrence of their migraine compared with 35% (95% CI 24%-48%) in the dexamethasone group (P = .68). At 30-day follow-up, this relative reduction in migraine recurrence decreased to a 4% difference between the 2 groups (P = .68). Limitations include small sample size and significant proportion lost to follow-up. CONCLUSION: A single dose of dexamethasone as adjunctive therapy for migraine headache does not decrease the recurrence of migraines at 3 or 30 days.
David Donaldson; Ryan Sundermann; Raymond Jackson; Aveh Bastani
Related Documents :
8394239 - Long-term experience with sumatriptan in the treatment of migraine.
21182229 - Tissue factor in predicted severe acute pancreatitis.
11279719 - Ropinirole versus bromocriptine for levodopa-induced complications in parkinson's disease.
21115239 - Intrahepatic radiofrequency ablation versus electrochemical treatment in vivo.
10836289 - Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atyp...
2375239 - Clinical and computer-based assessment of long-term therapeutic efficacy of propranolol...
10357489 - Interventional radiology and the use of metal stents in nonvascular clinical practice: ...
24082179 - Oral ketotifen and topical antibiotic therapy in the management of pruritus in prurigo ...
7949749 - A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermitt...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of emergency medicine     Volume:  26     ISSN:  1532-8171     ISO Abbreviation:  Am J Emerg Med     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-14     Completed Date:  2008-02-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309942     Medline TA:  Am J Emerg Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  124-30     Citation Subset:  IM    
William Beaumont Hospital.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Dexamethasone / administration & dosage*
Double-Blind Method
Glucocorticoids / administration & dosage*
Infusions, Intravenous
Migraine Disorders / drug therapy,  prevention & control*
Recurrence / prevention & control*
Treatment Outcome
Reg. No./Substance:
0/Glucocorticoids; 50-02-2/Dexamethasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comparison of central venous and arterial base deficit as a predictor of survival in acute trauma.
Next Document:  Diagnostic room-air pulse oximetry: effects of smoking, race, and sex.